Legal Action News

Your news source for lawsuits and other civil legal matters

Legal Action Recently...

April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
March 2006
February 2006
January 2006
December 2005
November 2005
October 2005
September 2005
August 2005
July 2005
June 2005
May 2005
April 2005
March 2005
February 2005
January 2005
December 2004


Legal Action News RSS Feed
RSS Feed



 

Weitz and Luxenberg Responds to Bextra Recall

10 April 2005

Since October 2004, Manhattan personal injury firm Weitz & Luxenberg has accepted new clients who have been seriously injured by the pain reducing medication Bextra. Bextra was prescribed to millions of Americans to treat the pain associated with arthritis, menstrual discomfort, and other ailments. Now, in light of the Food and Drug Administration’s demand that Bextra’s manufacturer, Pfizer, pull the drug from the market, the firm anticipates an increase in individuals seeking to file suit to get compensation for their injuries.

On April 7, 2005 the FDA asked Pfizer, Inc. to withdraw the drug from the market because the overall risk versus benefit profile for the drug is unfavorable. Common risks associated with the drug include angina, heart attack, stroke, fatal skin reactions, and Stevens Johnson syndrome. Pfizer first acknowledged risks associated with Bextra in October of 2004. The American Heart Association soon after was presented with a report indicating patients using Bextra while recovering from heart surgery were 2.19 times more likely to suffer a stroke or heart attack than those taking placebos.

With the FDA’s request for the removal of the drug, there will undoubtedly be new awareness of the dangers associated with Bextra, and many users will want to know their rights and means of legal recourse. Weitz and Luxenberg has a dedicated team of lawyers and client relations specialists who have been reviewing Bextra claims for months, and who can answer questions and advise Bextra users of their best course of legal action. The public is also invited to visit Weitz and Luxenberg’s corporate website, http://www.weitzlux.com, to access the firm’s extensive Bextra resource center.

In addition to requesting Pfizer to pull Bextra from the market, the FDA has also asked the company to include a boxed warning in the Celebrex label highlighting the potential for increased risk of cardiovascular (CV) events and gastrointestinal (GI) bleeding associated with its use.

Personal injury law firms such as Weitz & Luxenberg are concentrating on the most serious Bextra and Celebrex-related injuries; heart attacks, strokes, severe skin reactions, Stevens Johnson Syndrome, and death, paying particular attention to the dosage and frequency with which the drugs were taken when evaluating potential lawsuits.

People who have been injured by Bextra or Celebrex can contact Weitz & Luxenberg. Interested parties should call the Client Relations Department at 1 (800) 476-6070, email e-mail protected from spam bots, and view the firm's website at http://www.weitzlux.com.

Contact:
David Kufeld, Director of Marketing
Weitz & Luxenberg, PC
180 Maiden Lane, New York, NY 10038
(212) 558-5682 - phone
(212) 558-5692 - fax
e-mail protected from spam bots




Source: PR Web


All trademarks and copyrighted information contained herein are the property of their respective owners.

 
Law News



A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z